Top

World Journal of Surgery

Published in:

01-03-2013

Low Expression of PAI-2 as a Novel Marker of Portal Vein Tumor Thrombosis and Poor Prognosis in Hepatocellular Carcinoma

Authors: Li Zhou, Ye Jin, Quan-Cai Cui, Ke-Min Jin, Wei-Xun Zhou, Bao-Cai Xing

Published in: World Journal of Surgery | Issue 3/2013

Abstract

Background

Plasminogen activator inhibitor (PAI)-2 was previously shown to be less frequently expressed in hepatocellular carcinoma (HCC). The present study was designed to investigate the clinical, pathological, and prognostic significance of PAI-2 expression in HCC.

Methods

Expression of PAI-2 was detected immunohistochemically for specimens from 78 patients with HCC after hepatic resection and correlated with clinicopathological features and patient survival. Risk factors of portal vein tumor thrombosis (PVTT) were also analyzed.

Results

Positive PAI-2 staining was observed in tumor and non-tumor tissues from 21 (26.9 %) and 56 (71.8 %) patients, respectively. Plasminogen activator inhibitor-2 negativity in tumor tissues was significantly associated with PVTT, with a high sensitivity not only in univariate analysis but also in multivariate analysis. In addition, positive PAI-2 staining was related to smaller tumor size and prolonged patient survival. The Cox regression model identified intratumoral PAI-2 staining as an independent prognosticator in patients with HCC after resection.

Conclusions

Our data demonstrated that low expression of PAI-2 serves as a novel marker of PVTT and poor prognosis in HCC.

Parkin DM, Pisani P, Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594–606PubMedCrossRef

Pisani P, Parkin DM, Bray F et al (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18–29PubMedCrossRef

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Zhang XF, Meng B, Qi X et al (2009) Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: surgeon’s role in survival. Eur J Surg Oncol 35:622–628PubMedCrossRef

Lam VW, Ng KK, Chok KS et al (2008) Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 207:20–29PubMedCrossRef

Thuluvath PJ, Maheshwari A, Thuluvath NP et al (2009) Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus. Liver Transpl 15:754–762PubMedCrossRef

Tandon P, Garcia-Tsao G (2009) Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 29:502–510PubMedCrossRef

Itoh T, Hayashi Y, Kanamaru T et al (2000) Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 15:422–430PubMedCrossRef

Wong N, Yeo W, Wong WL et al (2009) TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patient survival and chemoresistance. Int J Cancer 124:644–652PubMedCrossRef

10.

Ke AW, Shi GM, Zhou J et al (2009) Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49:491–503PubMedCrossRef

11.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRef

12.

Dass K, Ahmad A, Azmi AS et al (2008) Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34:122–136PubMedCrossRef

13.

Croucher DR, Saunders DN, Lobov S et al (2008) Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 8:535–545PubMedCrossRef

14.

Nordengren J, Fredstorp Lidebring M et al (2002) High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int J Cancer 97:379–385PubMedCrossRef

15.

Champelovier P, Boucard N, Levacher G et al (2002) Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Urol Res 30:301–309PubMedCrossRef

16.

Meijer-van Gelder ME, Look MP, Peters HA et al (2004) Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 64:4563–4568PubMedCrossRef

17.

Smith R, Xue A, Gill A et al (2007) High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg 31:493–502. doi:10.1007/s00268-006-0289-9 PubMedCrossRef

18.

Zhou L, Hayashi Y, Itoh T et al (2000) Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma. Pathol Int 50:392–397PubMedCrossRef

19.

Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503PubMedCrossRef

20.

Hasina R, Hulett K, Bicciato S et al (2003) Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res 63:555–559PubMed

21.

Kaibori M, Ishizaki M, Matsui K et al (2010) Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol 102:462–468PubMedCrossRef

22.

Kim SJ, Lee KK, Kim DG (2010) Tumor size predicts the biological behavior and influence of operative modalities in hepatocellular carcinoma. Hepatogastroenterology 57:121–126PubMed

23.

Wang T, Hu HS, Feng YX et al (2010) Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br J Cancer 102:1618–1626PubMedCrossRef

24.

Zhou L, Rui JA, Wang SB et al (2006) Clinicopathological features, post-surgical survival and prognostic indicators of elderly patients with hepatocellular carcinoma. Eur J Surg Oncol 32:767–772PubMedCrossRef

25.

Darnell GA, Antalis TM, Johnstone RW et al (2003) Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol Cell Biol 23:6520–6532PubMedCrossRef

26.

Takahashi C, Ewen ME (2006) Genetic interaction between Rb and N-ras: differentiation control and metastasis. Cancer Res 66:9345–9348PubMedCrossRef

27.

Arima Y, Inoue Y, Shibata T et al (2008) Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 68:5104–5112PubMedCrossRef

28.

De Petro G, Tavian D, Copeta A et al (1998) Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 58:2234–2239PubMed

Title: Low Expression of PAI-2 as a Novel Marker of Portal Vein Tumor Thrombosis and Poor Prognosis in Hepatocellular Carcinoma
Authors: Li Zhou
Ye Jin
Quan-Cai Cui
Ke-Min Jin
Wei-Xun Zhou
Bao-Cai Xing
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 3/2013
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-012-1866-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Low Expression of PAI-2 as a Novel Marker of Portal Vein Tumor Thrombosis and Poor Prognosis in Hepatocellular Carcinoma

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2013

Mortality Pattern in Surgical Wards of a University Teaching Hospital in Southwest Nigeria: A Review

Laparoscopic Versus Open Surgery for Stage I Rectal Cancer: Long-term Oncologic Outcomes

Efficacy of Cholestyramine Ointment in Reduction of Postoperative Pain and Pain during Defecation after Open Hemorrhoidectomy: Results of a Prospective, Single-center, Randomized, Double-blind, Placebo-controlled Trial

Lateral Incisional Hernia Repair by the Retromuscular Approach with Polyester Standard Mesh: Topographic Considerations and Long-term Follow-up of 61 Consecutive Patients

One-stage Resection for Bismuth Type IV Hilar Cholangiocarcinoma with High Hilar Resection and Parenchyma-preserving Strategies: A Cohort Study

Indians Fit the Asian Trauma Model